PYRUKYND (mitapivat sulfate)
ANTIHEMOLYTIC - PYRUVATE KINASE (PK) ACTIVATOR · HEMOLYTIC ANEMIA DUE TO PYRUVATE KINASE DEFICIENCY
AGIOS PHARMACEU
Drug class
Antihemolytic - Pyruvate Kinase (PK) Activator
The label "Antihemolytic - Pyruvate Kinase (PK) Activator" represents a hybrid classification reflecting therapeutic intent and mechanism, while the standard FDA established pharmacologic class (EPC) is simply "pyruvate kinase activator." These agents allosterically bind to red blood cell pyruvate kinase, enhancing glycolytic enzyme activity to boost cellular adenosine triphosphate (ATP) production and decrease 2,3-diphosphoglycerate levels. Read more about Antihemolytic - Pyruvate Kinase (PK) Activator
3 drugs in this class 1 manufacturers
Drugs in Antihemolytic - Pyruvate Kinase (PK) Activator
PYRUKYND (mitapivat sulfate)
ANTIHEMOLYTIC - PYRUVATE KINASE (PK) ACTIVATOR · HEMOLYTIC ANEMIA DUE TO PYRUVATE KINASE DEFICIENCY
AGIOS PHARMACEU
AQVESME (mitapivat sulfate)
ANTIHEMOLYTIC - PYRUVATE KINASE (PK) ACTIVATOR · ANEMIA IN BETA THALASSEMIA ·+1
AGIOS PHARMACEU
Filter & compare in the drug finder →
Opens the drug finder with Antihemolytic - Pyruvate Kinase (PK) Activator preselected. Add indication or manufacturer filters there.
The label "Antihemolytic - Pyruvate Kinase (PK) Activator" represents a hybrid classification reflecting therapeutic intent and mechanism, while the standard FDA established pharmacologic class (EPC) is simply "pyruvate kinase activator." These agents allosterically bind to red blood cell pyruvate kinase, enhancing glycolytic enzyme activity to boost cellular adenosine triphosphate (ATP) production and decrease 2,3-diphosphoglycerate levels.
This metabolic restoration improves red blood cell membrane stability and survival, producing an antihemolytic effect that directly mitigates premature erythrocyte destruction.
Clinically, the class is used to treat hemolytic anemia associated with hereditary pyruvate kinase deficiency and is under active investigation for broader hemolytic hemoglobinopathies, including thalassemia and sickle cell disease.
-
fda.gov
The label "Antihemolytic - Pyruvate Kinase (PK) Activator" represents a hybrid classification reflecting therapeutic intent and mechanism, while the standard FDA established pharmacologic class (EPC) is simply "pyruvate kinase activator." Clinically, the class is used to treat hemolytic anemia associated with hereditary pyruvate kinase deficiency and is under active investigation for broader hemolytic hemoglobinopathies, including thalassemia and sickle cell disease.
-
fda.gov
The label "Antihemolytic - Pyruvate Kinase (PK) Activator" represents a hybrid classification reflecting therapeutic intent and mechanism, while the standard FDA established pharmacologic class (EPC) is simply "pyruvate kinase activator."
-
fda.gov
These agents allosterically bind to red blood cell pyruvate kinase, enhancing glycolytic enzyme activity to boost cellular adenosine triphosphate (ATP) production and decrease 2,3-diphosphoglycerate levels.
-
fda.gov
These agents allosterically bind to red blood cell pyruvate kinase, enhancing glycolytic enzyme activity to boost cellular adenosine triphosphate (ATP) production and decrease 2,3-diphosphoglycerate levels. Clinically, the class is used to treat hemolytic anemia associated with hereditary pyruvate kinase deficiency and is under active investigation for broader hemolytic hemoglobinopathies, including thalassemia and sickle cell disease.
-
drugs.com
These agents allosterically bind to red blood cell pyruvate kinase, enhancing glycolytic enzyme activity to boost cellular adenosine triphosphate (ATP) production and decrease 2,3-diphosphoglycerate levels. This metabolic restoration improves red blood cell membrane stability and survival, producing an antihemolytic effect that directly mitigates premature erythrocyte destruction.
-
fda.gov
This metabolic restoration improves red blood cell membrane stability and survival, producing an antihemolytic effect that directly mitigates premature erythrocyte destruction.
-
ashpublications.org
This metabolic restoration improves red blood cell membrane stability and survival, producing an antihemolytic effect that directly mitigates premature erythrocyte destruction. Clinically, the class is used to treat hemolytic anemia associated with hereditary pyruvate kinase deficiency and is under active investigation for broader hemolytic hemoglobinopathies, including thalassemia and sickle cell disease.
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.